In a recent Letter to the Editor \[[@B1]\], Talebi Bezmin Abadi commented on the paper by Arama et al. \[[@B2]\], in which the authors concluded that a 2-week regimen (Proton Pump inhibitor, plus Clarithromycin plus Amoxicillin) is preferable to a 7-day regimen as first-line therapy for*Helicobacter pylori* (*H. pylori*) infection. In his Letter, Talebi Bezmin Abadi concluded that "Certainly, preantibiotic susceptibility tests are inevitable approach in*H. pylori* therapy." Although we agree with all comments, we found the conclusion inappropriate.

The 4th Maastricht/Florence Consensus Conference recommended abandoning clarithromycin in empirical treatment when the prevalence of resistance is higher than 15--20% \[[@B3]\].

In the paper by Arama et al. \[[@B2]\], the overall eradication rate observed was 70.5%: the number of patients who responded to treatment was significantly greater in the 14-day treatment (84.6%) group compared to patients who received the 7-day treatment (42.3%) (*p* \< 0.001).

An acceptable eradication rate is differently defined in literature (\>75% \[[@B5]\], ≥ 90--95% \[[@B6]\]) and the clinicians should "use only what works locally" ignoring consensus statements and society guidelines if these are not consistent with local treatment results \[[@B7]\]. Moreover, antibiotic resistance should be considered as a dynamic concept, since its prevalence can change not only among different countries, but also between two different periods in the same area \[[@B8]\].

A culture-based approach, in clinical practice, is often unfeasible and its cost may be hard to afford \[[@B9]\]. Furthermore, the whole process needs a standard of quality (in terms of both materials used for culture and skill of the microbiologist to grow*H. pylori*) that cannot be assured everywhere \[[@B8]\]. Probably, the cost-effectiveness of the culture-based approach may change depending on host-related factors (bleeding, use of certain drugs) and methodology-related factors (number of gastric biopsies, conditions of transport, and laboratory characteristics) \[[@B8]\]. These factors may be favorable in some settings compared to others.

Hence, in the year 2016 a culture-guided treatment must be taken into account only in settings with experience in this issue and after failure of previous regimens.
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